A study to investigate the efficacy of ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic neuroendocrine tumors of the pancreas

You likely can't join if

• - Pregnancy or lactation. - Secondary malignancy in patient's history with the exception of: disease-free period > 5 years before randomization or non-melanoma skin cancer or curatively treated cervical carcinoma in situ or other noninvasive in situ neoplasm. - Allergy against dacarbazine or ramucirumab - Current enrolment or participation within the last 4 weeks in a clinical drug trial - Any arterial thromboembolic events within 6 months prior to first dose of protocol therapy. Insufficient liver function - Uncontrolled or poorly-controlled hypertension (>160 mmHg systolic or > 100 mmHg diastolic for >4 weeks) despite standard medical management - Chronic antiplatelet therapy, once-daily aspirin use (maximum dose 325 mg/day) permitted - Grade 3-4 GI bleeding within 3 months prior to first dose of protocol therapy. - History of deep vein thrombosis (DVT), pulmonary embolism (PE), or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered "significant") during the 3 months prior to first dose of protocol therapy - Uncontrolled severe physical or mental disorders - Pathological condition present that carries a high risk of bleeding - History of gastrointestinal perforation/fistula (within 6 months of first dose of protocol therapy) or risk factors for perforation. - Major surgery within 28 days prior to first dose of protocol therapy, or minor surgery/subcutaneous venous access device placement within 7 days prior to first dose of protocol therapy. Elective or planned major surgery to be performed during the course of the clinical trial. - Serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to first dose of protocol therapy. - officially and/or legally accomodated persons